Total Payments
$185,005
2024 Payments
$63,412
Companies
33
Transactions
325
Medicare Patients
2,755
Medicare Billing
$396,844
Payment Breakdown by Category
Other$123,973 (67.0%)
Consulting$24,596 (13.3%)
Research$16,302 (8.8%)
Travel$12,031 (6.5%)
Food & Beverage$8,103 (4.4%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $123,973 | 38 | 67.0% |
| Consulting Fee | $24,596 | 13 | 13.3% |
| Unspecified | $16,302 | 5 | 8.8% |
| Travel and Lodging | $12,031 | 25 | 6.5% |
| Food and Beverage | $8,103 | 244 | 4.4% |
Payments by Type
General
$168,704
320 transactions
Research
$16,302
5 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GENZYME CORPORATION | $54,345 | 56 | $0 (2024) |
| Regeneron Healthcare Solutions, Inc. | $49,293 | 47 | $0 (2024) |
| GlaxoSmithKline, LLC. | $25,909 | 51 | $0 (2024) |
| AERIN MEDICAL INC. | $18,478 | 21 | $0 (2024) |
| Neurent Medical Limited | $15,989 | 4 | $0 (2024) |
| Intersect ENT, Inc. | $12,275 | 15 | $0 (2022) |
| Regeneron Pharmaceuticals, Inc. | $4,694 | 3 | $0 (2024) |
| Spirair, Inc. | $1,276 | 2 | $0 (2024) |
| Optinose US, Inc. | $742.11 | 47 | $0 (2024) |
| Aroa Biosurgery Incorporated | $239.91 | 5 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $63,412 | 78 | Neurent Medical Limited ($15,989) |
| 2023 | $32,175 | 59 | GlaxoSmithKline, LLC. ($15,347) |
| 2022 | $43,943 | 71 | GENZYME CORPORATION ($20,199) |
| 2021 | $39,861 | 52 | Regeneron Healthcare Solutions, Inc. ($16,234) |
| 2020 | $4,257 | 11 | Regeneron Healthcare Solutions, Inc. ($4,103) |
| 2019 | $411.19 | 26 | Intersect ENT, Inc. ($192.43) |
| 2018 | $298.19 | 13 | Acclarent, Inc ($115.75) |
| 2017 | $647.42 | 15 | Intersect ENT, Inc. ($230.53) |
All Payment Transactions
325 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | Neurent Medical Limited | NEUROMARK Device (Device), NEUROMARK Radiofrequency Console | — | Cash or cash equivalent | $10,343.50 | Research |
| Study: Release Study - Clinical Exploration of NEUROMARK System in Subjects With Chronic Migraine • Category: Electrosurgical, Cutting & Coagulation & Accessories | ||||||
| 12/17/2024 | Neurent Medical Limited | NEUROMARK Device (Device), NEUROMARK Radiofrequency Console | — | Cash or cash equivalent | $846.00 | Research |
| Study: NEUROMARK Randomized Controlled Trial • Category: Electrosurgical, Cutting & Coagulation & Accessories | ||||||
| 12/16/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $22.16 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 12/11/2024 | Optinose US, Inc. | Xhance (Drug) | Food and Beverage | In-kind items and services | $26.55 | General |
| Category: Otolaryngology (Ear, Nose, Throat) | ||||||
| 11/20/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $34.15 | General |
| Category: Immunology | ||||||
| 11/20/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $14.81 | General |
| Category: IMMUNOLOGY | ||||||
| 11/07/2024 | Neurent Medical Limited | NEUROMARK Device (Device), NEUROMARK Radiofrequency Console | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: NEUROMARK Randomized Controlled Trial • Category: Electrosurgical, Cutting & Coagulation & Accessories | ||||||
| 11/07/2024 | Neurent Medical Limited | NEUROMARK Device (Device), NEUROMARK Radiofrequency Console | — | Cash or cash equivalent | $2,299.50 | Research |
| Study: Release Study - Clinical Exploration of NEUROMARK System in Subjects With Chronic Migraine • Category: Electrosurgical, Cutting & Coagulation & Accessories | ||||||
| 11/04/2024 | Regeneron Healthcare Solutions, Inc. | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $31.90 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/25/2024 | Regeneron Pharmaceuticals, Inc. | DUPIXENT (Biological) | Consulting Fee | Cash or cash equivalent | $1,956.00 | General |
| Category: INFLAMMATION AND IMMUNOLOGY | ||||||
| 10/21/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $24.94 | General |
| Category: Immunology | ||||||
| 10/17/2024 | GENZYME CORPORATION | — | Consulting Fee | Cash or cash equivalent | $1,060.00 | General |
| 10/16/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $16.72 | General |
| Category: IMMUNOLOGY | ||||||
| 10/14/2024 | ABBVIE INC. | UBRELVY (Drug), QULIPTA | Food and Beverage | In-kind items and services | $15.28 | General |
| Category: NEUROSCIENCE | ||||||
| 10/02/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $32.34 | General |
| Category: Immunology | ||||||
| 09/30/2024 | AERIN MEDICAL INC. | VIVAER STYLUS (Device) | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| Category: EAR NOSE & THROAT | ||||||
| 09/27/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $109.04 | General |
| Category: IMMUNOLOGY | ||||||
| 09/27/2024 | KARL STORZ Endoscopy-America | Solo+ TTD Handpiece (Device) | Food and Beverage | In-kind items and services | $49.70 | General |
| Category: ENT | ||||||
| 09/23/2024 | GlaxoSmithKline, LLC. | NUCALA (Biological) | Food and Beverage | In-kind items and services | $19.99 | General |
| Category: IMMUNOLOGY | ||||||
| 09/22/2024 | Spirair, Inc. | SeptAlign (Device), SeptAlign | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| Category: Otolarynology | ||||||
| 09/22/2024 | AERIN MEDICAL INC. | VIVAER STYLUS (Device) | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| Category: EAR NOSE & THROAT | ||||||
| 09/13/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,586.00 | General |
| Category: Immunology | ||||||
| 09/12/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $6,846.00 | General |
| Category: Immunology | ||||||
| 09/12/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Travel and Lodging | Cash or cash equivalent | $233.16 | General |
| Category: Immunology | ||||||
| 09/12/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Travel and Lodging | In-kind items and services | $187.89 | General |
| Category: Immunology | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Release Study - Clinical Exploration of NEUROMARK System in Subjects With Chronic Migraine | Neurent Medical Limited | $12,643 | 2 |
| NEUROMARK Randomized Controlled Trial | Neurent Medical Limited | $3,346 | 2 |
| ASSESSING LONG-TERM OUTCOMES OF DUPIXENT TREATMENT IN PATIENTS WITH CHRONIC RHINOSINUSITIS WITH NASAL POLYPOSIS (AROMA) | Regeneron Pharmaceuticals, Inc. | $312.60 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 622 | 925 | $234,163 | $104,000 |
| 2022 | 12 | 604 | 932 | $216,179 | $101,908 |
| 2021 | 15 | 678 | 986 | $198,208 | $96,976 |
| 2020 | 16 | 851 | 1,176 | $196,799 | $93,959 |
Total Patients
2,755
Total Services
4,019
Medicare Billing
$396,844
Procedure Codes
52
All Medicare Procedures & Services
52 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 31231 | Diagnostic exam of nasal passages using an endoscope | Office | 2023 | 163 | 265 | $66,725 | $32,816 | 49.2% |
| 31237 | Biopsy or removal of nasal polyp or tissue using an endoscope | Office | 2023 | 18 | 92 | $55,566 | $20,407 | 36.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 129 | 183 | $20,130 | $15,273 | 75.9% |
| 31579 | Exam to assess movement of vocal cord flaps using an endoscope | Office | 2023 | 67 | 89 | $36,757 | $12,024 | 32.7% |
| 70486 | Ct scan of face without contrast | Office | 2023 | 79 | 101 | $25,250 | $9,039 | 35.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 47 | 64 | $7,360 | $4,129 | 56.1% |
| 76377 | 3d radiographic procedure with computerized image postprocessing | Office | 2023 | 58 | 69 | $12,075 | $3,761 | 31.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 32 | 32 | $6,400 | $3,493 | 54.6% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 29 | 30 | $3,900 | $3,058 | 78.4% |
| 31231 | Diagnostic exam of nasal passages using an endoscope | Office | 2022 | 156 | 297 | $74,250 | $38,693 | 52.1% |
| 31237 | Biopsy or removal of nasal polyp or tissue using an endoscope | Office | 2022 | 18 | 58 | $37,043 | $13,274 | 35.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 102 | 164 | $18,860 | $11,028 | 58.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 92 | 122 | $13,420 | $10,515 | 78.4% |
| 31579 | Exam to assess movement of vocal cord flaps using an endoscope | Office | 2022 | 61 | 74 | $30,562 | $10,084 | 33.0% |
| 70486 | Ct scan of face without contrast | Office | 2022 | 70 | 88 | $22,000 | $8,141 | 37.0% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 32 | 32 | $6,400 | $3,886 | 60.7% |
| 92612 | Evaluation and recording of swallowing using an endoscope | Office | 2022 | 13 | 13 | $2,470 | $1,868 | 75.6% |
| 92507 | Treatment of speech, language, voice, communication, and/or hearing processing disorder | Office | 2022 | 12 | 32 | $4,000 | $1,706 | 42.7% |
| 76377 | 3d radiographic procedure with computerized image postprocessing | Office | 2022 | 24 | 28 | $4,900 | $1,414 | 28.9% |
| 92524 | Analysis of voice and resonance production | Office | 2022 | 11 | 11 | $1,650 | $931.46 | 56.5% |
| 92613 | Evaluation, recording, and interpretation of swallowing using an endoscope | Office | 2022 | 13 | 13 | $624.00 | $367.29 | 58.9% |
| 31231 | Diagnostic examination of nasal passages using an endoscope | Office | 2021 | 150 | 284 | $71,000 | $38,059 | 53.6% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 100 | 152 | $17,210 | $10,345 | 60.1% |
| 31579 | Examination to assess movement of vocal cord flaps using an endoscope | Office | 2021 | 46 | 63 | $26,019 | $8,831 | 33.9% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 73 | 73 | $13,720 | $8,637 | 63.0% |
About Dr. John Davis, M.D
Dr. John Davis, M.D is a Otolaryngology healthcare provider based in Hoover, Alabama. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1124113501.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. John Davis, M.D has received a total of $185,005 in payments from pharmaceutical and medical device companies, with $63,412 received in 2024. These payments were reported across 325 transactions from 33 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($123,973).
As a Medicare-enrolled provider, Davis has provided services to 2,755 Medicare beneficiaries, totaling 4,019 services with total Medicare billing of $396,844. Data is available for 4 years (2020–2023), covering 52 distinct procedure/service records.
Ad
Practice Information
- Specialty Otolaryngology
- Location Hoover, AL
- Active Since 10/03/2006
- Last Updated 01/16/2025
- Taxonomy Code 207Y00000X
- Entity Type Individual
- NPI Number 1124113501
Products in Payments
- DUPIXENT (Biological) $106,624
- NUCALA (Biological) $25,909
- VIVAER STYLUS (Device) $18,259
- NEUROMARK Device (Device) $15,989
- SeptAlign (Device) $1,276
- PROPEL (Device) $962.41
- Xhance (Drug) $742.11
- Clarifix (Device) $133.19
- ACCLARENT Balloon Inflation Device (Device) $115.75
- INSPIRE (Device) $114.18
- QULIPTA (Drug) $113.85
- Cook Medical Biodesign (Device) $97.88
- SPECTRA WAVEWRITER (Device) $95.34
- SINUVA (Drug) $79.29
- Otiprio (Drug) $79.16
- Otovel (Drug) $72.97
- UBRELVY (Drug) $65.79
- PK Diego (Device) $49.99
- Solo+ TTD Handpiece (Device) $49.70
- DRILLCUT-X II SHAVER HANDPIECE (Device) $47.94
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.